| pubmed-article:9186536 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9186536 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9186536 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9186536 | lifeskim:mentions | umls-concept:C0014822 | lld:lifeskim |
| pubmed-article:9186536 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9186536 | pubmed:dateCreated | 1997-7-7 | lld:pubmed |
| pubmed-article:9186536 | pubmed:abstractText | The efficacy and safety of recombinant human erythropoietin (rhEPO) were tested when given subcutaneously (s.c.) in an escalating dose of 2000-10,000 units (U) daily in 60 patients with cancer-related anaemia (CRA). A positive response, defined as an increase in haemoglobin more than 2 g/dl and independence of blood transfusions was observed in 23 of 48 evaluable patients (48%) within a median of 8 wk. In detail, rhEPO corrected anaemia in 11 of 14 patients (79%) with malignant lymphoma, in 8 of 15 patients (53%) with multiple myeloma and in 4 of 10 patients (40%) with a solid tumour. The median dose of rhEPO in successful cases was 5000 U daily. Four patients with agnogenic myeloid metaplasia and 5 with myelodysplastic disorder failed to respond to rhEPO. No patient had any severe side effects. Pretreatment serum erythropoietin levels appeared to be a weak predictor for response to rhEPO treatment. In conclusion, rhEPO seems to be safe and effective in correcting CRA in certain groups of patients. | lld:pubmed |
| pubmed-article:9186536 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9186536 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9186536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9186536 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9186536 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:9186536 | pubmed:issn | 0902-4441 | lld:pubmed |
| pubmed-article:9186536 | pubmed:author | pubmed-author:SeeberSS | lld:pubmed |
| pubmed-article:9186536 | pubmed:author | pubmed-author:NowrousianM... | lld:pubmed |
| pubmed-article:9186536 | pubmed:author | pubmed-author:WelzKK | lld:pubmed |
| pubmed-article:9186536 | pubmed:author | pubmed-author:FossåAA | lld:pubmed |
| pubmed-article:9186536 | pubmed:author | pubmed-author:KasperCC | lld:pubmed |
| pubmed-article:9186536 | pubmed:author | pubmed-author:TerhaarAA | lld:pubmed |
| pubmed-article:9186536 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9186536 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:9186536 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9186536 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9186536 | pubmed:pagination | 251-6 | lld:pubmed |
| pubmed-article:9186536 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:meshHeading | pubmed-meshheading:9186536-... | lld:pubmed |
| pubmed-article:9186536 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9186536 | pubmed:articleTitle | Recombinant human erythropoietin in the treatment of cancer-related anaemia. | lld:pubmed |
| pubmed-article:9186536 | pubmed:affiliation | Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Germany. | lld:pubmed |
| pubmed-article:9186536 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9186536 | pubmed:publicationType | Clinical Trial | lld:pubmed |
